TriStar Health Partners

  • Home
  • About
    • TriStar
    • Team
  • News
  • Investment Strategy
    • Investment Strategy
    • Economic Development Fund – TN Investco
  • Portfolio
  • Contact

BioStable Science & Engineering Initiates European Commercialization of the HAART™ 300 Aortic Annuloplasty Device

May 18, 2016 By tstventures2015

BioStable Science & Engineering, Inc. announced today that the first commercial implantation of its HAART 300 Aortic Annuloplasty Device was performed by Dr. Domenico Mazzitelli on Wednesday, May 11th, at the German Heart Center Munich. Additional procedures were completed on Friday, May 13th, by Professor Yeong-Hoon Choi at the University of Cologne Heart Center. These two respected heart centers were the first selected to receive the HAART 300 Aortic Annuloplasty Device as part of the limited commercial launch of the technology announced by the company in March. (read more)

Filed Under: News

Our Portfolio


VIEW MORE

Subscribe to News & Events

Contact Us

Thank you for your interest in TriStar Health Partners. If you have questions or need further information, please contact us!

TriStar Health Partners

3322 West End Ave, Suite 1100 | Nashville, TN 37203
615.515-9880

Copyright © 2023 TriStar Technology Ventures. All rights reserved (CC-licensed photos excepted).